# Dynepo Infrequent Dosing Study

> **NCT00450333** · PHASE3 · TERMINATED · sponsor: **Shire** · enrollment: 407 (actual)

## Conditions studied

- Anemia
- Kidney Failure

## Interventions

- **DRUG:** Dynepo (Epoetin delta)
- **DRUG:** Dynepo
- **DRUG:** Dynepo
- **DRUG:** Dynepo

## Key facts

- **NCT ID:** NCT00450333
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10-30
- **Primary completion:** 2008-07-31
- **Final completion:** 2008-07-31
- **Target enrollment:** 407 (ACTUAL)
- **Why stopped:** The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450333, "Dynepo Infrequent Dosing Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00450333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*